Central Nervous System Neoplasm
📧 Sign up to get email alerts when something new happens for Central Nervous System Neoplasm.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: HyperArc Registry Study
The HyperArc Registry Study sponsored by Varian (a Siemens Healthineers company) has completed, evaluating HyperArc for brain metastases and…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors [Phase 1]
Volitinib is being studied in a Phase 1 trial for patients with recurrent or refractory primary CNS tumors, with the study currently listed …
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors [NA]
This ClinicalTrials.gov update reports completion of an investigational 7T MRI imaging study for central nervous system tumors, with results…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types [Phase 2]
Phase 2 trial update indicating access to pembrolizumab for selected rare cancer types has been secured.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]
Phase 1 trial update on entinostat in pediatric patients with recurrent or refractory solid tumors, completed with results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-28Clinical Trial Update: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors [Phase 2]
A Phase 2 clinical trial evaluating cabozantinib-s-maleate in pediatric patients with recurrent, refractory, or newly diagnosed sarcomas, Wi…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating adavosertib in combination with irinotecan hydrochloride for relapsed or refractory solid tumors in younger patie…
-
CLINICAL_TRIALS trial_result · 2021-03-26Clinical Trial Update: Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating talazoparib with temozolomide in younger patients with refractory or recurrent solid tumors; study completed with…
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors [Phase 2]
Phase 2 trial evaluating temozolomide and irinotecan with or without bevacizumab in young patients with recurrent or refractory medulloblast…
-
CLINICAL_TRIALS trial_result · 2017-01-13Clinical Trial Update: Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas [Phase 2]
Phase 2 clinical trial evaluating radiation therapy with temozolomide and lomustine in young patients with newly diagnosed gliomas; complete…
-
CLINICAL_TRIALS trial_result · 2016-10-03Clinical Trial Update: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors [Phase 1]
This Phase 1 trial evaluates trebananib in younger patients with relapsed or refractory solid tumors, including central nervous system tumor…
-
CLINICAL_TRIALS trial_result · 2013-10-29Clinical Trial Update: Temozolomide in Treating Patients With Recurrent High-Grade Glioma [Phase 2]
Phase 2 clinical trial of temozolomide in patients with recurrent high-grade glioma has completed with results posted in 2013.